  The treatment paradigm for metastatic nonsquamous non-small-cell lung cancer ( nsclc) continues to change. Algorithms published only 6 months ago are outdated today and are dramatically different from those published a few years ago. New driver mutations continue to be identified , and the development of therapies to inhibit oncogenic addiction is ongoing. Patient survival is improving as treatments become more personalized and effective. This review looks at the outcomes of recent trials and discusses treatment options for patients with metastatic nsclc of nonsquamous histology. Algorithms continue to change quickly , and an attempt is made to keep the paradigm current and applicable into the near future. Treatment algorithms for nsclc tumours with The treatment algorithm for